Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a pioneering biopharmaceutical company headquartered in Vancouver, British Columbia. Focused on neurology, Xenon leverages its proprietary discovery platform, termed 'extreme genetics', to develop innovative medications. The company’s approach involves studying families with severe phenotypes to identify single-gene defects, which offer insights into human biology and serve as potential drug targets.
Xenon’s development pipeline targets a range of neurological disorders, particularly epilepsy and depression. The flagship product, XEN1101, is a potent, selective potassium channel opener currently in various phases of clinical trials for epilepsy and major depressive disorder (MDD). Xenon has ongoing Phase 3 trials for XEN1101 in focal onset seizures (X-TOLE2, X-TOLE3) and primary generalized tonic-clonic seizures (X-ACKT). The drug has shown promising efficacy in reducing seizures and improving quality of life in long-term extension studies.
Additionally, Xenon is exploring XEN1101's potential in treating MDD, with a Phase 3 program expected to begin in 2024. Recent interim data from the X-NOVA Phase 2 trial revealed significant improvements in depression symptoms, supporting further development for this indication. Xenon’s pre-clinical work includes investigations into Nav1.1 and Nav1.7 potentiators for various neurological conditions.
Key developments include a partnership with Neurocrine Biosciences to develop XEN901 (NBI-921352) for epilepsy. Xenon's financial stability, robust clinical pipeline, and strategic collaborations position it for continued growth and innovation in neurology-focused therapeutics.
Recent Achievements:
- Strong presence at AES 2023 with multiple presentations on XEN1101
- Presented new data from the Phase 2b X-TOLE trial demonstrating significant seizure freedom rates
- Expanded open-label extension study collecting over 500 patient years of data
- Announced positive topline results from X-NOVA Phase 2 trial for MDD
- Ongoing collaboration with Icahn School of Medicine for additional MDD studies
For more updates and detailed information, visit the official website.
Xenon Pharmaceuticals Inc. has successfully closed its underwritten public offering of 10,000,000 common shares, including 1,525,423 shares from the underwriters’ option, and pre-funded warrants for 1,694,915 shares. The shares were priced at $29.50 each, with pre-funded warrants at $29.4999. The gross proceeds from this offering totaled approximately $345 million, prior to expenses. The offering followed an effective shelf registration statement filed with the SEC on October 4, 2021.
Xenon Pharmaceuticals has announced a public offering of 8,474,577 common shares and 1,694,915 pre-funded warrants, priced at $29.50 and $29.4999 respectively. The offering aims to raise approximately $300 million in gross proceeds, which will support the company's clinical stage developments. The offering is set to close on or about October 8, 2021. The underwriters have a 30-day option to purchase an additional 1,525,423 shares at the offering price. Jefferies, SVB Leerink, Stifel, and RBC Capital Markets are leading the offering.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has initiated an underwritten public offering of $250 million in common shares, with an option for underwriters to purchase an additional $37.5 million. The offering is made under an existing shelf registration statement filed with the SEC. Notably, this process is subject to market conditions, and completion is not guaranteed. Notable underwriters include Jefferies, SVB Leerink, Stifel, and RBC Capital Markets. The company emphasizes that no securities are being offered in Canada.
Xenon Pharmaceuticals (Nasdaq:XENE) reported promising results from its Phase 2b X-TOLE clinical trial for XEN1101, aimed at treating focal epilepsy. The trial showcased statistically significant reductions in monthly focal seizure frequency across all dose groups, with p-values under 0.001 for the 20 mg and 25 mg doses. A median reduction of 52.8% was noted for the highest dose, compared to 18.2% for placebo. The encouraging outcomes support XEN1101's efficacy and safety, with plans to collaborate with the FDA for expedited development and a long-term study extension now set for three years.
Xenon Pharmaceuticals (Nasdaq:XENE) will host a conference call and webcast on October 4, 2021, at 7:30 AM ET to discuss topline results from the XEN1101 Phase 2b “X-TOLE” clinical trial. Investors can join the conference call by dialing (855) 779-9075 in the U.S. or (631) 485-4866 internationally, using conference ID number 4481713. The call will be available on the Xenon website for replay after the event. Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals announced a $10 million milestone payment from Neurocrine Biosciences after gaining regulatory approval for a clinical trial application in Europe. This payment includes $4.5 million in cash and a $5.5 million equity investment at a premium price of $19.9755 per share. Xenon collaborates with Neurocrine on NBI-921352, aimed at treating focal-onset seizures and SCN8A developmental and epileptic encephalopathy. Phase 2 trials for both conditions are expected to begin later in 2021, reflecting progress in epilepsy treatment options.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has appointed Dr. Christopher Kenney as Chief Medical Officer. Dr. Kenney will lead clinical development and medical affairs strategies for the company's neurology-focused therapeutic programs. CEO Ian Mortimer expressed optimism about Dr. Kenney's extensive experience in clinical development and neuroscience, especially as the company prepares for the topline data from its XEN1101 Phase 2b X-TOLE study, expected in late September to mid-October. Dr. Kenney has over 20 years of experience in the field, including roles at Cadent Therapeutics and Acorda Therapeutics.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its Q2 2021 financial results, revealing a net loss of $22.1 million, up from $0.2 million a year prior, primarily due to reduced revenue and increased expenses. Total revenue fell to $2.2 million from $13.4 million in Q2 2020. Cash and equivalents rose to $260.5 million, expected to fund operations into 2023. The company anticipates topline data from the Phase 2b XEN1101 X-TOLE trial by mid-October, a potential inflection point. Clinical trials for XEN496 and XEN007 are ongoing, with other partnered milestones expected in 2021.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 12th Annual Wedbush PacGrow Healthcare Conference. The company will engage in one-on-one investor meetings and a virtual panel discussion titled “Got My Mind Set On You - Advancing Novel Epilepsy Targets.”
The panel is scheduled for August 11, 2021, from 11:30 am to 12 pm Eastern Time, featuring Dr. Simon Pimstone, Executive Chair of the Board. Interested parties can find further details and a link to the live webcast on the Investors section of Xenon's website.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will announce its Q2 2021 financial results after the U.S. markets close on August 11, 2021. Management will hold a conference call and live audio webcast at 4:30 pm ET to discuss these results and provide corporate updates. Investors can access the webcast via the Xenon website. The details are subject to change, and webcasts will be available for replay after the event.
FAQ
What is the current stock price of Xenon Pharmaceuticals (XENE)?
What is the market cap of Xenon Pharmaceuticals (XENE)?
What does Xenon Pharmaceuticals specialize in?
What is the focus of Xenon’s proprietary discovery platform?
What is XEN1101?
What are the recent achievements of Xenon Pharmaceuticals?
Who are Xenon’s strategic partners?
What are Xenon’s key products in the pipeline?
What is the status of the XEN1101 epilepsy trials?
How can I contact Xenon Pharmaceuticals for investor information?
Where is Xenon Pharmaceuticals headquartered?
What is the significance of Xenon’s pre-clinical work?
